Oncology Biomarker Development

Oncology Biomarker Development

Oncology Biomarker Development

Oncology Biomarker DevelopmentPublications:Arthur LM, Turnbull AK, Renshaw L, Keys J, Thomas JS, Wilson TR, Lackner MR, Sims AH, Dixon JM: Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer. Breast cancer research and treatment 2014, 147(1):211-219.Schleifman EB, Desai R, Spoerke JM, Xiao Y, Wong C, Abbas I, O'Brien C, Patel R, Sumiyoshi T, Fu L et al: Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers. PLoS One 2014, 9(2):e88401.Wilson TR, Xiao Y, Spoerke JM, Fridlyand J, Koeppen H, Fuentes E, Huw LY, Abbas I, Gower A, Schleifman EB et al: Development of a robust RNA-based classifier to accurately determine ER, PR, and HER2 status in breast cancer clinical samples. Breast cancer research and treatment 2014, 148(2):315-325.Edgar KA, Crocker L, Cheng E, Wagle MC, Wongchenko M, Yan Y, Wilson TR, Dompe N, Neve RM, Belvin M et al: Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition. Genes & cancer 2014, 5(3-4):113-126.Wilson TR, Lackner MR: Changing the paradigm: circulating tumor DNA as a ‘liquid biopsy’ for clinical biomarker assessments. Clinical Investigation 2014, 4(12):1083-1093.Shames DS, Carbon J, Walter K, Jubb AM, Kozlowski C, Januario T, Do A, Fu L, Xiao Y, Raja R et al: High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck. PLoS One 2013, 8(2):e56765.Huw LY, O'Brien C, Pandita A, Mohan S, Spoerke JM, Lu S, Wang Y, Hampton GM, Wilson TR, Lackner MR: Acquired PIK3CA amplification causes resistance to selective phosphoinositide 3-kinase inhibitors in breast cancer. Oncogenesis 2013, 2:e83.

Mentor: Jeff Settleman.Discovery Oncology/ Kinase Addiction/ Signal TransductionPublications:Timothy R. Wilson, Jane Fridlyand, Yibing Yan, Elicia Penuel, Luciana Burton, Emily Chan, Jing Peng, Eva Lin, Yulei Wang, Jeff Sosman, Antoni Ribas, Jiang Li, John Moffat, Daniel P. Sutherlin, Hartmut Koeppen, Mark Merchant, Richard Neve & Jeff Settleman (2012). Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509.Raha D, Wilson TR, Peng J, Peterson D, Yue P, Evangelista M, Wilson C, Merchant M, Settleman J: The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation. Cancer Res 2014, 74(13):3579-3590.Wilson, K. J., Mill, C., Lambert, S., Buchman, J., Wilson, T. R., Hernandez-Gordillo, V., Gallo, R. M., Ades, L. M., Settleman, J., and Riese, D. J. (2012). EGFR ligands exhibit functional differences in models of paracrine and autocrine signaling. Growth Factors.Wilson, T. R., Lee, D. Y., Berry, L., Shames, D. S., and Settleman, J. (2011). Neuregulin-1-Mediated Autocrine Signaling Underlies Sensitivity to HER2 Kinase Inhibitors in a Subset of Human Cancers. Cancer Cell 20, 158-172.

Mentor: Jeff Settleman.Discovery Oncology/ Signal Transduction/ Kinase Addiction

Publications:Logan, A. E., Wilson, T. R., Fenning, C., Cummins, R., Kay, E., Johnston, P. G., and Longley, D. B. (2010). In vitro and in vivo characterisation of a novel c-FLIP-targeted antisense phosphorothioate oligonucleotide. Apoptosis 15, 1435-1443.Wilson, T. R., Johnston, P. G., and Longley, D. B. (2009). Anti-apoptotic mechanisms of drug resistance in cancer. Curr Cancer Drug Targets 9, 307-319.Wilson, T. R., McEwan, M., McLaughlin, K., Le Clorennec, C., Allen, W. L., Fennell, D. A., Johnston, P. G., and Longley, D. B. (2009). Combined inhibition of FLIP and XIAP induces Bax-independent apoptosis in type II colorectal cancer cells. Oncogene 28, 63-72.Wilson, T. R., Redmond, K. M., McLaughlin, K. M., Crawford, N., Gately, K., O'Byrne, K., Le-Clorrenec, C., Holohan, C., Fennell, D. A., Johnston, P. G., and Longley, D. B. (2009). Procaspase 8 overexpression in non-small-cell lung cancer promotes apoptosis induced by FLIP silencing. Cell Death Differ 16, 1352-1361.Wilson, C., Wilson, T., Johnston, P. G., Longley, D. B., and Waugh, D. J. (2008). Interleukin-8 signaling attenuates TRAIL- and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Mol Cancer Ther 7, 2649-2661.Redmond, K. M., Wilson, T. R., Johnston, P. G., and Longley, D. B. (2008). Resistance mechanisms to cancer chemotherapy. Front Biosci 13, 5138-5154.Rogers, K. M., Thomas, M., Galligan, L., Wilson, T. R., Allen, W. L., Sakai, H., Johnston, P. G., and Longley, D. B. (2007). Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells. Mol Cancer Ther 6, 1544-1551.Wilson, T. R., McLaughlin, K. M., McEwan, M., Sakai, H., Rogers, K. M., Redmond, K. M., Johnston, P. G., and Longley, D. B. (2007). c-FLIP: a key regulator of colorectal cancer cell death. Cancer Res 67, 5754-5762.Wilson, T. R., Longley, D. B., and Johnston, P. G. (2006). Chemoresistance in solid tumours. Ann Oncol 17 Suppl 10, x315-324.